PE20020959A1 - CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELLOMERASE AGENTS - Google Patents

CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELLOMERASE AGENTS

Info

Publication number
PE20020959A1
PE20020959A1 PE2002000227A PE2002000227A PE20020959A1 PE 20020959 A1 PE20020959 A1 PE 20020959A1 PE 2002000227 A PE2002000227 A PE 2002000227A PE 2002000227 A PE2002000227 A PE 2002000227A PE 20020959 A1 PE20020959 A1 PE 20020959A1
Authority
PE
Peru
Prior art keywords
amino
nil
methyl
triazine
quinoli
Prior art date
Application number
PE2002000227A
Other languages
Spanish (es)
Inventor
Patrick Mailliet
Abdelazize Laoui
Gilles Doerflinger
Francois Hamy
Thomas Caulfield
Jean-Louis Mergny
Jean-Francois Riou
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103916A external-priority patent/FR2822468B1/en
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20020959A1 publication Critical patent/PE20020959A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN AGENTE REPARTIDOR LIGADO A GRUPOS AMINO AROMATICOS DE FORMULA: CICLOAROMATICO NITROGENADO-NR3-DISTRIBUIDOR-NR'3-CICLO AROMATICO; DONDE CICLOAROMATICO NITROGENADO ES QUINOLEINA, ISOQUINOLEINA, BENZAMIDINA, PIRIDINA; CICLO AROMATICO REPRESENTA QUINOLEINA SUSTITUIDO POR N(Ra)(Rb); BENZAMIDINA, PIRIDINA, FENILO, HETEROCICLO MONO, BI, TRICICLICO; Ra, Rb SON H, ALQUILO C1-C4, ALCOXI C1-C4. R3, R'3 SON TRIAZINA SUSTITUDO, DIAZINA SUSTITUIDO. SON COMPUESTOS PREFERIDOS 2,4-BIS-(4-DIMETILAMINO-2-METIL-QUINOLI-6-NIL)AMINO-6-(3-DIMETILAMINO-PROPIL)AMINO-[1,3,5]TRIAZINA; 2,4,6-TRIS-(4-AMINO-2-METIL-QUINOLI-6-NIL)AMINO-[1,3,5]TRIAZINA, 2,4-BIS-(4-AMINO-2-METIL-QUINOLI-6-NIL)AMINO-6-(4-DIMETILAMINO-2-METIL-QUINOLI-6-NIL)-AMINO-[1,3,5]TRIAZINA, 2,4-BIS-(4-DIMETILAMINO-2-METIL-QUINOLI-6-NIL)AMINO-6-((1-METIL-PIPERIDI-4-NIL)-[1,3,5]TRIAZINA, ENTRE OTROS. LOS COMPUESTOS NO NUCLEOTIDOS INTERACTUAN CON ESTRUCTURAS ESPECIFICAS DEL ADN O ARN, SON INHIBIDORES DE TELOMERASA VIA LA ESTABILIZACION DE G-CUADRUPLEXAS, Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE CANCERREFERS TO A DISTRIBUTION AGENT LINKED TO AMINO AROMATIC GROUPS OF FORMULA: NITROGEN CYCLOAROMATICO-NR3-DISTRIBUIDOR-NR'3-AROMATIC CYCLE; WHERE NITROGEN CYCLOAROMATIC IS QUINOLEIN, ISOQUINOLEIN, BENZAMIDINE, PYRIDINE; AROMATIC CYCLE REPRESENTS QUINOLEIN SUBSTITUTED BY N (Ra) (Rb); BENZAMIDINE, PYRIDINE, PHENYL, HETEROCICLO MONO, BI, TRICYCLIC; Ra, Rb SON H, C1-C4 ALKYL, C1-C4 ALCOXY. R3, R'3 ARE SUBSTITUTE TRIAZINE, SUBSTITUTE DIAZINE. PREFERRED COMPOUNDS ARE 2,4-BIS- (4-DIMETHYLAMINO-2-METHYL-QUINOLI-6-NIL) AMINO-6- (3-DIMETHYLAMINO-PROPYL) AMINO- [1,3,5] TRIAZINE; 2,4,6-TRIS- (4-AMINO-2-METHYL-QUINOLI-6-NIL) AMINO- [1,3,5] TRIAZINE, 2,4-BIS- (4-AMINO-2-METHYL-QUINOLI -6-NIL) AMINO-6- (4-DIMETHYLAMINO-2-METHYL-QUINOLY-6-NIL) -AMINO- [1,3,5] TRIAZINE, 2,4-BIS- (4-DIMETHYLAMINO-2-METHYL -QUINOLI-6-NIL) AMINO-6 - ((1-METHYL-PIPERIDI-4-NIL) - [1,3,5] TRIAZINE, AMONG OTHERS, NON-NUCLEOTIDE COMPOUNDS INTERACT WITH SPECIFIC STRUCTURES OF DNA OR RNA, ARE TELOMERASE INHIBITORS VIA THE STABILIZATION OF G-QUADRUPLEXES, AND MAY BE USEFUL FOR THE TREATMENT OF CANCER

PE2002000227A 2001-03-23 2002-03-22 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELLOMERASE AGENTS PE20020959A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0103916A FR2822468B1 (en) 2001-03-23 2001-03-23 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTI-TELOMERASE AGENT
FR0110370 2001-08-02

Publications (1)

Publication Number Publication Date
PE20020959A1 true PE20020959A1 (en) 2002-12-17

Family

ID=26212933

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000227A PE20020959A1 (en) 2001-03-23 2002-03-22 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELLOMERASE AGENTS

Country Status (11)

Country Link
EP (1) EP1373252A1 (en)
JP (1) JP2004524349A (en)
AR (1) AR034297A1 (en)
AU (1) AU2002251140B2 (en)
CA (1) CA2442012A1 (en)
CO (1) CO5380035A1 (en)
IL (2) IL158056A0 (en)
MX (1) MXPA03008269A (en)
MY (1) MY130957A (en)
PE (1) PE20020959A1 (en)
WO (1) WO2002076975A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096903A2 (en) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004001018A2 (en) * 2002-06-25 2003-12-31 The Center For Blood Research, Inc. Vacuolins
FR2850970B1 (en) * 2003-02-07 2006-07-07 Aventis Pharma Sa CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
EP1881835A4 (en) * 2005-05-19 2010-04-07 Prometic Biosciences Inc Triazine compounds and compositions thereof for the treatment of cancers
EP2441757A1 (en) * 2006-07-31 2012-04-18 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
CN101808693A (en) * 2007-07-25 2010-08-18 百时美施贵宝公司 Triazine kinase inhibitors
FR2948686B1 (en) * 2009-07-30 2011-08-19 Biomerieux Sa NEW PEPTIDASE SUBSTRATES
JP7284518B2 (en) * 2018-03-20 2023-05-31 国立大学法人広島大学 Compound that inhibits telomere-binding protein, and telomere-binding protein inhibitor containing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (en) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd Triazine derivative and telomerase inhibitor
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
SK7402002A3 (en) * 1999-11-29 2002-11-06 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
WO2003066099A1 (en) * 2002-02-05 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. 2,4,6-triamino-1,3,5-triazine derivative

Also Published As

Publication number Publication date
AU2002251140B2 (en) 2007-03-15
CO5380035A1 (en) 2004-03-31
AR034297A1 (en) 2004-02-18
JP2004524349A (en) 2004-08-12
EP1373252A1 (en) 2004-01-02
IL158056A (en) 2010-02-17
IL158056A0 (en) 2004-03-28
WO2002076975A1 (en) 2002-10-03
CA2442012A1 (en) 2002-10-03
MXPA03008269A (en) 2004-10-15
MY130957A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
PE20191613A1 (en) PYRAZOLE [1,5-A] PYRIDINE COMPOUNDS SUBSTITUTED AS INHIBITORS OF RET KINASE
PE20020959A1 (en) CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELLOMERASE AGENTS
PE20010912A1 (en) ARILAMINE DERIVATIVES AND ITS APPLICATION AS ANTITELOMERASE AGENTS
DE602004023838D1 (en) HEMMER OF ACT ACTIVITY
DE602004026047D1 (en) HEMMER OF ACT ACTIVITY
BRPI0514371A (en) 2,4 di (aminophenyl) pyrimidine as plk inhibitors
PE20020305A1 (en) 2- (4-PYRIDYL) AMINO-6-DIALCOXYPHENYL-PYRIDO [2,3-d] PYRIMIDIN-7-ONAS AS INHIBITORS OF TYROSINE KINASE
DE60227492D1 (en) INGREDIENTS OF THE ACT ACTIVITY
UY27234A1 (en) NOVELTY INHIBITORS OF TYROSINE KINASE
AR029383A1 (en) SMALL MOLECULES, THE INTERMEDIARIES FOR THEIR SYNTHESIS, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT INTENDED FOR TREATMENT OR PROPHYLAXIS OF INFLAMMATORY DISEASES OR MEDIATIONED BY IMMUNE CELLS
ECSP105253A (en) DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS INHIBITORS OF PI3 CINASA
CO5700778A2 (en) COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS
PE20010211A1 (en) THIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEIN KINASES
NO20035583D0 (en) Imidazo` 1,2-A pyridine derivatives for prophylaxis and treatment of herpes viral infections
PA8501801A1 (en) TRIMYCLY POLYMERASE INHIBITORS (ADP - POLIRRIBOSAS)
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
GT200100016A (en) PIRIDO [2,3, -D] PYRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES.
ME00595B (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
BR0308854A (en) Substituted benzazoles and their uses as raf kinase inhibitors
AP2000002016A0 (en) 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
EP1633740A4 (en) Chemical compounds
SE9702564D0 (en) New compounds
ATE452896T1 (en) C3-CYANOEPOTHILONE DERIVATIVES
YU75603A (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed